Abstract:After 4 years of the COVID-19 pandemic, SARS-CoV-2 continues to circulate with epidemic waves caused by evolving new variants. Although the rapid development of vaccines and approved antiviral drugs has reduced virus transmission and mitigated the symptoms of infection, the continuous emergence of new variants and the lack of simple-use (non-hospitalized, easy timing, local delivery, direct acting, and host-targeting) treatment modalities have limited the effectiveness of COVID-19 vaccines and drugs. Therefore, novel therapeutic approaches against SARS-CoV-2 infection are still urgently needed. As a positive-sense single-stranded RNA virus, SARS-CoV-2 is highly susceptible to RNA interference (RNAi). Accordingly, small interfering (si)RNAs targeting different regions of SARS-CoV-2 genome can effectively block the expression and replication of the virus. However, the rapid emergence of new SARS-CoV-2 variants with different genomic mutations has led to the problem of viral escape from the targets of RNAi strategy, which has increased the potential of off-target effects by siRNA and decreased the efficacy of long-term use of siRNA treatment. In our study, we enzymatically generated a set of Dicer-substrate (D)siRNA swarms containing DsiRNAs targeting single or multiple conserved sequences of SARS-CoV-2 genome by using in vitro transcription, replication and Dicer digestion system. Pre-transfection of these DsiRNA swarms into Vero E6-TMPRSS2 cells inhibited the replication of several SARS-CoV-2 variants, including the recent Omicron subvariants BQ.1.1 and XBB.1.5. This in vitro investigation of novel DsiRNA swarms provides solid evidence for the feasibility of this new RNAi strategy in the prevention and treatment of SARS-CoV-2 infection.

Inhibition of Severe Acute Respiratory Syndrome Virus Replication by Small Interfering RNAs in Mammalian Cells

Therapeutic and Prophylactic Potential of Small Interfering RNAs Against Severe Acute Respiratory Syndrome

Inhibition Of Sars-Cov Gene Expression By Adenovirus-Delivered Small Hairpin Rna

Inhibiting Severe Acute Respiratory Syndrome-Associated Coronavirus by Small Interfering Rna

Prophylactic and Therapeutic Effects of Small Interfering RNA Targeting SARS-coronavirus.

Inhibition of Genes Expression of SARS Coronavirus by Synthetic Small Interfering RNAs

Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference.

Small Interfering Rna Inhibits Sars-Cov Nucleocapsid Gene Expression in Cultured Cells and Mouse Muscles

Inhibition of Gene Expression Directed by Small Interfering Rnas in Infectious Bronchitis Virus

siRNA designs to the crucial proteins of SARS coronavirus

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

RNAi Therapeutics: Can Sirnas Conquer SARS?

Inhibition of SARS-CoV Infection in Vero-E6 Cells by Sirnas

Rapid Identification of Small Interfering Rna That Can Effectively Inhibit the Replication of Multiple Influenza B Virus Strains

Silencing of SARS-CoV Spike Gene by Small Interfering RNA in HEK 293T Cells

Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

Virus-specific Dicer-substrate siRNA swarms inhibit SARS-CoV-2 infection in TMPRSS2-expressing Vero E6 cells

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination

Inhibition of Influenza Virus Production in Virus-Infected Mice by RNA Interference.

Small Interfering Rna-Mediated Inhibition Of Respiratory Syncytial Virus Infections In Hela Cells

Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque